Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to
Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus
AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im
Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc
Southampton, UK-based start-up Curve Therapeutics has completed a £40.5 million ($51 million) in Series A financing for its drug discovery platform that enables drug scree
Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.